Search results with tag "Highlights of prescribing information these"
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.novartis.usHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KESIMPTA safely and effectively. See full prescribing information for KESIMPTA. or live vaccines is not recommended during treatment with KESIMPTA® (ofatumumab) injection, for subcutaneous use Initial U.S. Approval: 2009
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
media.allergan.comAug 29, 2017 · HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LATISSE safely and effectively. See full prescribing information for LATISSE. LATISSE® (bimatoprost ophthalmic solution) 0.03%, for topical ophthalmic use Initial U.S. Approval: 2001 _____INDICATIONS AND USAGE_____
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use SKYLA safely and effectively. See full prescribing information for SKYLA. SKYLA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 •-----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.alnylam.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ONPATTRO® safely and effectively. See full prescribing information for ONPATTRO. ONPATTRO (patisiran) lipid complex injection, for intravenous use Initial U.S. Approval: 2018 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
qsymia.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use QSYMIA ® safely and effectively. See full prescribing information for QSYMIA. QSYMIA (phentermine and topiramate extended-release) capsules, for oral use, CIV . Initial U.S. Approval: 2012 .
HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - …
www.xermelo.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XERMELO safely and effectively. See full prescribing information for
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use MIRENA safely and effectively. See full prescribing information for MIRENA. MIRENA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 ---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use SKYLA safely and effectively. See full prescribing information for SKYLA. SKYLA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 •---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.astellas.usFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE VESIcare® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. 2 DOSAGE AND ADMINISTRATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.accessdata.fda.govA vial adapter is supplied for use when reconstituting the lyophilized powder. However, the vial adapter should not be used if multiple doses are going to be withdrawn from the vial.